Stoke Therapeutics, Inc.

4.05 USD
+0.01 (+0.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Stoke Therapeutics, Inc. stock is up 13.45% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 November’s closed higher than October. 100% of analysts rate it a buy.

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy.